Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Heekyung Ahn


Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242


H. Ahn1, S.H. Hyun2, S. Park3, S.J. Lee4, J.Y. Kim3, J.S. Ahn5, Y. Im6, Y.H. Park3

Author affiliations

  • 1 Medical Oncology, Gachon University Gil Medical Center, 405-760 - Incheon/KR
  • 2 Nuclear Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 3 Hematology-oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 4 Medicine, EWHA Womans University Hospital, 07804 - Seoul/KR
  • 5 Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 6 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center, 06351 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1565


Metabolic tumor volume(MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography(FDG PET/CT) was correlated with prognosis in various cancers. The aim of this study was to investigate the prognostic value of MTV in metastatic breast cancer (MBC).


We retrospectively reviewed 172 patients who underwent FDG PET/CT at diagnosis of MBC at a single center. MTV for the whole body tumor lesions were measured by FDG PET/CT. The prognostic significance of MTV and other clinicopathological variables for progression free survival (PFS) to the first line palliative treatment(1L-PFS) was assessed by Kaplan-Meier method and Cox proportional hazards regression analysis.


Median age was 45 years (range 27-71). 76 patients had hormone receptor-positive(HR+)/human epidermal receptor-2 negative(HER2-) disease, 55 patients had HER2+ and 41 patients had triple negative breast cancer(TNBC). In the univariate analysis, TNBC subtype and higher MTV was associated with worse 1L-PFS. On multivariate analysis adjusted for age, presence of visceral metastases, and liver involvement, indepent predictive factors associated with decreased 1L-PFS were TNBC (HR 2.724 versus HR+/HER2 subtype, p = 0.002) and MTV (HR 1.165 with doubling of MTV, p = 0.001).


MTV, a volumetric parameter of FDG PET/CT, is an important independent prognostic factor for PFS to the first line palliative treatment, irrespective of tumor subtype, in patients with MBC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


Y.H. Park: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): Eisai; Advisory / Consultancy, Research grant / Funding (self): Novartis; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.